189 related articles for article (PubMed ID: 12810454)
1. Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors.
Cascinu S; Georgoulias V; Kerr D; Maughan T; Labianca R; Ychou M
Ann Oncol; 2003; 14 Suppl 2():ii25-9. PubMed ID: 12810454
[TBL] [Abstract][Full Text] [Related]
2. Current treatments and future perspectives in colorectal and gastric cancer.
Wilke HJ; Van Cutsem E
Ann Oncol; 2003; 14 Suppl 2():ii49-55. PubMed ID: 12810459
[TBL] [Abstract][Full Text] [Related]
3. Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial.
Thomaidis T; Maderer A; Formentini A; Bauer S; Trautmann M; Schwarz M; Neumann W; Kittner JM; Schad A; Link KH; Rey JW; Weinmann A; Hoffman A; Galle PR; Kornmann M; Moehler M
J Exp Clin Cancer Res; 2014 Oct; 33(1):83. PubMed ID: 25272957
[TBL] [Abstract][Full Text] [Related]
4. A systematic overview of chemotherapy effects in colorectal cancer.
Ragnhammar P; Hafström L; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):282-308. PubMed ID: 11441937
[TBL] [Abstract][Full Text] [Related]
5. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
Saltz LB; Douillard JY; Pirotta N; Alakl M; Gruia G; Awad L; Elfring GL; Locker PK; Miller LL
Oncologist; 2001; 6(1):81-91. PubMed ID: 11161231
[TBL] [Abstract][Full Text] [Related]
6. Current status of adjuvant therapy for colorectal cancer.
O'Connell MJ
Oncology (Williston Park); 2004 May; 18(6):751-5; discussion 755-8. PubMed ID: 15214594
[TBL] [Abstract][Full Text] [Related]
7. [Combination of 5-Fluorouracil and folinic acid--is it still the standard therapy for advanced colorectal carcinoma?].
Carnaghi C; Zucali P; Garassino I
Tumori; 2000; 86(5 Suppl 2):S19-25. PubMed ID: 11195298
[TBL] [Abstract][Full Text] [Related]
8. Irinotecan-based combinations for the adjuvant treatment of stage III colon cancer.
Saltz L
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 14):47-50. PubMed ID: 11200149
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer.
Underhill C; Goldstein D; Gorbounova VA; Biakhov MY; Bazin IS; Granov DA; Hossain AM; Blatter J; Kaiser C; Ma D
Oncology; 2007; 73(1-2):9-20. PubMed ID: 18334829
[TBL] [Abstract][Full Text] [Related]
10. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.
Bertagnolli MM; Niedzwiecki D; Compton CC; Hahn HP; Hall M; Damas B; Jewell SD; Mayer RJ; Goldberg RM; Saltz LB; Warren RS; Redston M
J Clin Oncol; 2009 Apr; 27(11):1814-21. PubMed ID: 19273709
[TBL] [Abstract][Full Text] [Related]
11. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy.
Edler D; Glimelius B; Hallström M; Jakobsen A; Johnston PG; Magnusson I; Ragnhammar P; Blomgren H
J Clin Oncol; 2002 Apr; 20(7):1721-8. PubMed ID: 11919227
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of 5-fluorouracil metabolic enzymes as predictors of response to adjuvant chemotherapy outcomes in patients with stage II/III colorectal cancer: a decision-curve analysis.
Shigeta K; Ishii Y; Hasegawa H; Okabayashi K; Kitagawa Y
World J Surg; 2014 Dec; 38(12):3248-56. PubMed ID: 25167895
[TBL] [Abstract][Full Text] [Related]
13. A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma.
Graeven U; Arnold D; Reinacher-Schick A; Heuer T; Nusch A; Porschen R; Schmiegel W
Onkologie; 2007 Apr; 30(4):169-74. PubMed ID: 17396039
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.
Van Cutsem E; Labianca R; Bodoky G; Barone C; Aranda E; Nordlinger B; Topham C; Tabernero J; André T; Sobrero AF; Mini E; Greil R; Di Costanzo F; Collette L; Cisar L; Zhang X; Khayat D; Bokemeyer C; Roth AD; Cunningham D
J Clin Oncol; 2009 Jul; 27(19):3117-25. PubMed ID: 19451425
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant therapy of colon cancer.
Macdonald JS; Astrow AB
Semin Oncol; 2001 Feb; 28(1):30-40. PubMed ID: 11254865
[TBL] [Abstract][Full Text] [Related]
16. Irinotecan-based regimens in the adjuvant therapy of colorectal cancer.
Douillard JY
Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S34-7. PubMed ID: 15871764
[TBL] [Abstract][Full Text] [Related]
17. Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy.
Douillard JY; Sobrero A; Carnaghi C; Comella P; Díaz-Rubio E; Santoro A; Van Cutsem E
Ann Oncol; 2003; 14 Suppl 2():ii7-12. PubMed ID: 12810451
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant therapy of colon cancer.
Sun W; Haller DG
Semin Oncol; 2005 Feb; 32(1):95-102. PubMed ID: 15726511
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of adjuvant chemotherapy irinotecan + 5-fluorouracil + leucovorine in advanced colorectal cancer.
Kulig J; Popiela T; Richter P; Klek S
Acta Chir Belg; 2007 Jun; 107(3):297-301. PubMed ID: 17685257
[TBL] [Abstract][Full Text] [Related]
20. Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma.
Akbulut H; Altuntas F; Akbulut KG; Ozturk G; Cindoruk M; Unal E; Icli F
Cytokine; 2002 Nov; 20(4):184-90. PubMed ID: 12543084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
